CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders

Reuters03-04

<a href="https://laohu8.com/S/CRVO">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders

CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616582315?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616582315","market":"fut","top_or_hot":-1,"title":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL3yjjqz:1","article_id":"2616582315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616582315","pubTimestamp":1772629504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"CervoMed发布关于Neflamapimod开发治疗年龄相关脑部疾病的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"CervoMed Publishes Corporate Presentation on Neflamapimod Development for Age-Related Brain Disorders\n    \n\n        CervoMed Inc. highlighted its clinical-stage pipeline focused on age-related brain disorders, centered on its lead candidate neflamapimod, an oral small-molecule inhibitor of p38α intended to address neuroinflammation and synaptic dysfunction. The company outlined planned development steps for neflamapimod in dementia with Lewy bodies, including preparation for a Phase 3 study expected to initiate in the second half of 2026, and noted ongoing Phase 2a trials in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts anticipated in mid-2026 and the second half of 2026, respectively. The presentation also described prior Phase 2a and Phase 2b findings in dementia with Lewy bodies and discussed drug exposure differences between manufacturing batches used in the Phase 2b program. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616582315","isCrawlerRequest":true}